MedElevator
Войти в исследования Pathology, research and practice · 2026
Integrated pan-cancer profiling and experimental validation identify CCDC59 as a key driver and therapeutic biomarker in liver hepatocellular carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Kun, Wan Dan, Liang Xiao, Yao Lan, Li Ji, Liu Nanbin, Zhu Mengchen, Wang Hong, Liang Fanfan
Аннотация
BACKGROUND: CCDC59, a coiled-coil domain-containing (CCDC) family member, is involved in multiple diseases, yet its pan-cancer role remains largely unclear.
METHODS: We analyzed CCDC59 across cancers using The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), along with R and tools like STRING, TISIDB, and TISCH2. CCDC59 expression was validated in clinical samples via quantitative real-time PCR (RT-qPCR) and western blot. Functional assays (proliferation, colony formation, and transwell) and cell cycle analysis were performed in liver hepatocellular carcinoma (LIHC) cells after siRNA-mediated CCDC59 knockdown.
RESULTS: CCDC59 was overexpressed in most cancers, particularly in bladder cancer. Its expression correlated positively with tumor mutational burden (TMB) in 21 cancer types and with microsatellite instability (MSI) in 24 cancer types, suggesting diagnostic potential. High CCDC59 expression was associated with poor prognosis and multiple clinicopathological features in renal papillary cell carcinoma (KIRP) and LIHC. Protein-protein interaction (PPI) and enrichment analyses linked CCDC59 and its co-expressed genes to pathways related to DNA damage, epithelial-mesenchymal transition (EMT), cell cycle, and immune infiltration, with prominent expression observed in B cells. CCDC59 also correlated with ferroptosis- and m6A-related genes in KIRP and LIHC and was predicted to interact with multiple molecules. Experimental validation in LIHC tissues confirmed elevated CCDC59 expression, and its knockdown inhibited proliferation, colony formation, migration, and invasion, while inducing G1 arrest and reducing S phase cells in HepG2 and Hep3B cells.
CONCLUSION: CCDC59 is highly expressed in LIHC and other cancers, with potential diagnostic and prognostic value, and targeting it may improve immunotherapy and chemotherapy efficacy.
DATA AVAILABILITY: The bioinformatics datasets used in this study are available at the corresponding websites, and raw data used during experiments will be made available by the authors upon reasonable request.
METHODS: We analyzed CCDC59 across cancers using The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), along with R and tools like STRING, TISIDB, and TISCH2. CCDC59 expression was validated in clinical samples via quantitative real-time PCR (RT-qPCR) and western blot. Functional assays (proliferation, colony formation, and transwell) and cell cycle analysis were performed in liver hepatocellular carcinoma (LIHC) cells after siRNA-mediated CCDC59 knockdown.
RESULTS: CCDC59 was overexpressed in most cancers, particularly in bladder cancer. Its expression correlated positively with tumor mutational burden (TMB) in 21 cancer types and with microsatellite instability (MSI) in 24 cancer types, suggesting diagnostic potential. High CCDC59 expression was associated with poor prognosis and multiple clinicopathological features in renal papillary cell carcinoma (KIRP) and LIHC. Protein-protein interaction (PPI) and enrichment analyses linked CCDC59 and its co-expressed genes to pathways related to DNA damage, epithelial-mesenchymal transition (EMT), cell cycle, and immune infiltration, with prominent expression observed in B cells. CCDC59 also correlated with ferroptosis- and m6A-related genes in KIRP and LIHC and was predicted to interact with multiple molecules. Experimental validation in LIHC tissues confirmed elevated CCDC59 expression, and its knockdown inhibited proliferation, colony formation, migration, and invasion, while inducing G1 arrest and reducing S phase cells in HepG2 and Hep3B cells.
CONCLUSION: CCDC59 is highly expressed in LIHC and other cancers, with potential diagnostic and prognostic value, and targeting it may improve immunotherapy and chemotherapy efficacy.
DATA AVAILABILITY: The bioinformatics datasets used in this study are available at the corresponding websites, and raw data used during experiments will be made available by the authors upon reasonable request.